Press release
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will host a virtual KOL presentation of ARCT-810 Phase 2 interim data for Ornithine Transcarbamylase (OTC) deficiency on Monday, June 30, 2025, at 12:00 p.m. ET. The Company will issue a press release summarizing the data at 11 am ET, prior to the presentation.\n\n\nThe KOL presentation will review Arcturus’ interim clinical data from ARCT-810 Phase 2 trials evaluating the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency. In addition to the management team, the following KOLs will be participating in the presentation:\n\n\nMarshall Summar, MD, CEO at Uncommon Cures®\n\n\n\nPreviously Chief of the Division of Genetics and Metabolism, Director of the Rare Disease Institute and the Margaret O’Malley Chair of Genetic Medicine at Children’s National Hospital, Emeritus Professor of Pediatrics at The George Washington University. Dr. Summar is an internationally recognized expert in urea cycle disorders (UCDs) with over four decades of clinical, research, and policy leadership. He is a founding member and Executive Committee member of the NIH UCD Consortium, where he led national UCD diagnostic and treatment consensus efforts. For more than 20 years, he served on the Scientific Advisory Board of the National UCD Foundation and has advised numerous academic and industry initiatives. He is the author of over 40 UCD-related publications, including GeneReviews®, clinical guidelines, and multinational natural history studies. As an inventor, he holds patents for ammonia diagnostics and UCD-related technologies and has led translational research in critical care and neonatal disease. In recognition of his long-standing contributions to rare disease research and clinical infrastructure, he received the NORD Lifetime Achievement Award in 2022.\n\n\n\nJohannes Häberle, MD, Professor and Director, Head of Metabolic Laboratory, Division of Metabolism, Urea Cycle Disorders Translational Center at the University of Zurich\n\n\n\nGlobally recognized expert in pediatric metabolic medicine and...